| Primary |
| Prostate Cancer |
50.8% |
| Drug Use For Unknown Indication |
23.0% |
| Hypertension |
10.0% |
| Diabetes Mellitus |
2.1% |
| Medical Diet |
1.4% |
| Product Used For Unknown Indication |
1.4% |
| Depression |
1.2% |
| Prophylaxis |
1.2% |
| Prostate Cancer Metastatic |
1.2% |
| Angina Pectoris |
0.9% |
| Precocious Puberty |
0.9% |
| Analgesia |
0.7% |
| Anxiety |
0.7% |
| Breast Cancer |
0.7% |
| Cardiac Failure |
0.7% |
| Cardiac Failure Congestive |
0.7% |
| Arrhythmia |
0.5% |
| Benign Prostatic Hyperplasia |
0.5% |
| Coronary Artery Disease |
0.5% |
| Flushing |
0.5% |
|
| Prostatic Specific Antigen Increased |
17.4% |
| Drug Ineffective |
10.7% |
| Pulmonary Embolism |
7.4% |
| Injection Site Necrosis |
5.8% |
| Product Quality Issue |
5.8% |
| Injection Site Pain |
5.0% |
| Myalgia |
5.0% |
| Oedema Peripheral |
5.0% |
| Pain |
5.0% |
| Death |
3.3% |
| Hot Flush |
3.3% |
| Off Label Use |
3.3% |
| Prostate Cancer Metastatic |
3.3% |
| Suicidal Ideation |
3.3% |
| Syncope |
3.3% |
| Toxic Skin Eruption |
3.3% |
| Blood Testosterone Increased |
2.5% |
| Cardiac Failure |
2.5% |
| Diabetes Mellitus |
2.5% |
| Hemiparesis |
2.5% |
|
| Secondary |
| Prostate Cancer |
58.8% |
| Drug Use For Unknown Indication |
8.8% |
| Product Used For Unknown Indication |
7.7% |
| Hypertension |
6.6% |
| Glaucoma |
2.6% |
| Radical Prostatectomy |
2.2% |
| Prophylaxis |
2.0% |
| Supplementation Therapy |
1.7% |
| Parkinson's Disease |
1.0% |
| Precocious Puberty |
1.0% |
| Premedication |
1.0% |
| Prostate Cancer Stage I |
1.0% |
| Anxiety |
0.7% |
| Back Pain |
0.7% |
| Cardiac Failure |
0.7% |
| Erectile Dysfunction |
0.7% |
| Essential Hypertension |
0.7% |
| Insomnia |
0.7% |
| Metastases To Bone |
0.7% |
| Pain |
0.7% |
|
| Prostatic Specific Antigen Increased |
11.2% |
| Osteoporosis |
9.7% |
| Pulmonary Embolism |
9.7% |
| Neutropenia |
8.2% |
| Febrile Neutropenia |
7.5% |
| Hot Flush |
5.2% |
| Small Intestinal Obstruction |
5.2% |
| Drug Ineffective |
4.5% |
| Hyperhidrosis |
4.5% |
| Pneumonia |
4.5% |
| Weight Increased |
4.5% |
| Injection Site Mass |
3.7% |
| Loss Of Consciousness |
3.7% |
| Aspartate Aminotransferase Increased |
3.0% |
| Hyperkalaemia |
3.0% |
| Pathological Fracture |
3.0% |
| Ear Discomfort |
2.2% |
| Injection Site Scab |
2.2% |
| Injection Site Ulcer |
2.2% |
| Prothrombin Time Abnormal |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.1% |
| Prostate Cancer |
19.4% |
| Prostate Cancer Metastatic |
12.6% |
| Metastases To Bone |
6.4% |
| Nausea |
3.6% |
| Prophylaxis |
3.6% |
| Pain |
2.9% |
| Hormone Therapy |
2.7% |
| Cancer Pain |
2.6% |
| Hypertension |
2.6% |
| Back Pain |
2.3% |
| Vomiting |
2.3% |
| Parkinson's Disease |
2.2% |
| Drug Use For Unknown Indication |
1.9% |
| Sepsis |
1.8% |
| Bone Disorder |
1.6% |
| Gastrooesophageal Reflux Disease |
1.6% |
| Constipation |
1.5% |
| Cough |
1.3% |
| Bone Pain |
1.2% |
|
| Weight Decreased |
16.7% |
| Vomiting |
11.8% |
| Osteonecrosis Of Jaw |
11.1% |
| Death |
7.6% |
| Localised Oedema |
4.2% |
| Nausea |
4.2% |
| Pneumonia |
4.2% |
| Sepsis |
4.2% |
| Tooth Extraction |
4.2% |
| Osteonecrosis |
3.5% |
| Pyrexia |
3.5% |
| Transurethral Prostatectomy |
3.5% |
| Brachial Plexus Injury |
2.8% |
| Cerebrovascular Accident |
2.8% |
| Dizziness |
2.8% |
| Pigmentary Glaucoma |
2.8% |
| Renal Failure |
2.8% |
| Swelling |
2.8% |
| White Blood Cell Count Decreased |
2.8% |
| Anaemia |
2.1% |
|
| Interacting |
| Immunosuppressant Drug Therapy |
50.0% |
| Prostate Cancer |
50.0% |
|
| Ventricular Extrasystoles |
100.0% |
|
